Search results for "Amphotericin"

showing 10 items of 68 documents

Post-bronchoscopy fatal endobronchial hemorrhage in a woman with bronchopulmonary mucormycosis: a case report

2010

Abstract Introduction During infection, Mucorales fungi invade major blood vessels, leading to extensive necrosis, and in cases of extensive pulmonary disease, bleeding into the lungs may occur. Case presentation We report an unexpected event of post-bronchoscopy fatal endobronchial hemorrhage in a 62-year-old HIV-negative Italian woman with well controlled diabetes mellitus who presented with diffuse cavitated pulmonary lesions. Fiberoptic bronchoscopy revealed bilateral obstruction of the segmental bronchi. Fatal massive bleeding occurred after standard biopsy procedures. Histologic examination showed that the hyphae were more deeply colored by hematoxylin-eosin (H&E) than by other stains…

Mucoralesmedicine.medical_specialtybronchoscopySettore MED/17 - Malattie InfettiveSettore MED/21 - Chirurgia ToracicaPulmonary diseaselcsh:MedicineCase ReportSettore MED/10 - Malattie Dell'Apparato RespiratorioSettore MED/08 - Anatomia PatologicaExtensive Necrosismedicineendobronchial hemorrhageMedicine(all)Voriconazolebiologybusiness.industryMucormycosislcsh:RGeneral Medicinebiology.organism_classificationmedicine.diseaseSurgeryPost bronchoscopyLiposomal amphotericinbusinessmucormycosimedicine.drugJournal of Medical Case Reports
researchProduct

Anidulafungin in combination with amphotericin B against Aspergillus fumigatus.

2009

ABSTRACT We investigated the effects of anidulafungin alone and in combination with amphotericin B against Aspergillus fumigatus . Indifference was the only type of interaction observed in vitro. Anidulafungin at 1 and 5 mg/kg of body weight/day, amphotericin B at 1 mg/kg/day, and combination therapy prolonged the survival of mice with invasive aspergillosis. Anidulafungin at 5 mg/kg/day, alone and in combination with amphotericin B, reduced the kidney fungal burden. Overall, the combination was not superior to the most active single drug.

Settore MED/07 - Microbiologia E Microbiologia ClinicaAntifungal AgentsCombination therapymedicine.drug_classAntibioticsMicrobial Sensitivity TestsPharmacologyAspergillosisAnidulafunginKidneyAspergillus fumigatusMicrobiologyEchinocandinsMicePharmacotherapyAmphotericin BAmphotericin BmedicineAnimalsAspergillosisPharmacology (medical)Experimental TherapeuticsPharmacologyAspergillusbiologyAspergillus fumigatusaspergillus anidulafungin amphotericin BBrainbiology.organism_classificationmedicine.diseasebacterial infections and mycosesInfectious DiseasesAnidulafunginDrug Therapy Combinationmedicine.drugAntimicrobial agents and chemotherapy
researchProduct

Trichosporon beigelii pneumonia in a neutropenic patient.

1989

A case of pulmonary infection caused by Trichosporon beigelii is reported in an asthmatic patient undergoing steroid treatment who developed fever and lung infiltrates. Arthroconidia and blastoconidia were isolated from repeated sputum, bronchial aspirate and telescopic catheter samples. The infection coincided with neutropenia resulting from pyrazolone treatment. The response to amphotericin B treatment was favourable.

Microbiology (medical)Malemedicine.medical_specialtyNeutropeniaPrednisoloneTrichosporon beigeliiNeutropeniaOpportunistic InfectionsGastroenterologyTheophyllineTrichosporonAmphotericin BInternal medicinemedicineHumansPyrazolonesLungbiologyLung Diseases Fungalbusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral MedicinePneumoniaMiddle Agedmedicine.diseasebiology.organism_classificationAsthmarespiratory tract diseasesCatheterPneumoniaInfectious Diseasesmedicine.anatomical_structureImmunologySputumPyrazolesArthroconidiummedicine.symptombusinessmedicine.drugAgranulocytosisEuropean journal of clinical microbiologyinfectious diseases : official publication of the European Society of Clinical Microbiology
researchProduct

Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemi…

2019

Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, partic…

0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazolePLOS ONE
researchProduct

Genotyping and antifungal susceptibility of human subgingival Candida albicans isolates.

2002

Subgingival colonization by Candida albicans has been described in human immunodeficiency virus (HIV)-infected individuals, but subgingival isolates have scarcely been characterized, particularly with respect to genotype and antifungal susceptibility. A series of 29 subgingival strains of C. albicans isolated from nine HIV-infected individuals was typed by electrophoretic karyotyping and tested for susceptibility to fluconazole, itraconazole, the new investigational triazole posaconazole and amphotericin B. DNA typing showed genetic heterogeneity within subgingival isolates, as almost every individual harbored his/her own specific isolate. Genetic identity was usually demonstrated within or…

AdultMalePosaconazoleAntifungal AgentsItraconazoleDental PlaqueHIV InfectionsMicrobial Sensitivity TestsMicrobiologyPeriodontal pathogenGenetic HeterogeneityDrug Resistance FungalAmphotericin BGenotypeCandida albicansmedicineHumansCandida albicansDNA FungalMycological Typing TechniquesGeneral DentistryGenotypingFluconazolebiologyCell BiologyGeneral MedicineTriazolesbiology.organism_classificationVirologyCorpus albicansOtorhinolaryngologyKaryotypingFemaleItraconazoleFluconazolemedicine.drugArchives of oral biology
researchProduct

Description of an improved method for Blastocystis hominis culture and axenization

1996

An improved method for Blastocystis hominis culture and axenization was developed in the present study. Stool samples were cultured in prereduced Boeck-Drbohlav NHI modified medium (with several modifications) supplemented with antibiotics (0.4% ampicillin, 0.1% streptomycin, 0.0006% amphotericin B). Axenization was performed by the combination of partial purification of B. hominis by Ficoll-metrizoic acid gradient and inoculation in fresh medium containing active antibiotics against remaining bacteria. A total of 25 strains were obtained by this procedure. The time required for axenization ranged between 3 and 5 weeks. The generation time of axenic strains ranged from 6.6 to 12.1 h (mean +…

medicine.drug_classAntibioticsBlastocystis InfectionsMicrobiologyFecesAmpicillinAmphotericin BCentrifugation Density GradientmedicineAnimalsHumansBlastocystis hominisAxenicFecesBlastocystisGeneral VeterinarybiologyGeneral Medicinebiology.organism_classificationCulture MediaInfectious DiseasesStreptomycinInsect ScienceParasitologyCell DivisionBacteriamedicine.drugParasitology Research
researchProduct

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience

2004

Objectives To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposomal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed over a 10 year period in Italy. Patients and methods Patients included were diagnosed as having VL consecutively admitted from December 1992 to December 2001 at four main referral children's hospitals in Italy and treated with six intravenous doses of 3 mg/kg L-AmB given on days 1-5 and 10 (a total dose of 18 mg/kg). Demographic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy outcome were considered. Results A total of 164 HIV-negative children (m…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentFeverAntiprotozoal AgentsFluorescent Antibody TechniqueNutritional Statusitaly; leishmania infantum; therapyBone MarrowRecurrenceAmphotericin BInternal medicineAmphotericin BmedicineHumansPharmacology (medical)ChildAdverse effectleishmaniasisRetrospective StudiesPharmacologyDrug Carriersbiologybusiness.industryInfantRetrospective cohort studyLeishmaniasismedicine.diseasebiology.organism_classificationSurgeryRegimenTreatment OutcomeInfectious DiseasesVisceral leishmaniasisItalyEl NiñoChild PreschoolLiposomesLeishmaniasis VisceralFemaleLeishmania infantumbusinessmedicine.drug
researchProduct

Direct-acting antivirals and visceral leishmaniasis: a case report

2019

Abstract Background Visceral leishmaniasis is a vector-borne parasitic disease caused by protozoa belonging to the genus Leishmania. The clinical presentation of visceral leishmaniasis strictly depends on the host immunocompetency, whereas depressive conditions of the immune system impair the capability to resolve the infection and allow reactivation from sites of latency of the parasite. Case presentation We describe a case of visceral leishmaniasis (VL) that occurred in a patient with chronic hepatitis C treated with direct-acting antiviral drugs (DAA). The hypothesized mechanism is the alteration of protective inflammation mechanisms secondary to DAA therapy. Downregulation of type II an…

0301 basic medicineMaleSofosbuvir030106 microbiologyAntiprotozoal AgentsCase ReportDirect-acting antiviralAntiviral Agentslcsh:Infectious and parasitic diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemAmphotericin BRibavirinHumansMedicinelcsh:RC109-216030212 general & internal medicineLeishmania infantumAgedAntiviral AgentLeishmaniaVisceral Leishmaniasisbiologybusiness.industryCoinfectionRibavirinHepatitis CHepatitis C Chronicbiology.organism_classificationmedicine.diseaseLeishmaniaHepatitis CInfectious DiseasesVisceral leishmaniasischemistryAntiprotozoal AgentImmunologyCoinfectionVisceral LeishmaniasiLeishmaniasis VisceralLeishmania infantumSofosbuvirbusinessmedicine.drugHumanBMC Infectious Diseases
researchProduct

Disseminated fusariosis in immunocompromised patients

2011

Immunocompromised patients are at high risk of developing serious disseminated infections by opportunistic fungi (Aspergillus, Candida, and Fusarium spp), which frequently present as cutaneous lesions, sometimes as a first sign. Prolonged and deep neutropenia, immunodepressive treatments (systemic steroids and chemotherapy) and severe T-cell immunodeficiency are the most important risk factors. We report 2 patients with acute lymphoblastic leukemia, who developed multiple tender erythematous skin lesions on their legs and arms during chemotherapy treatment. Skin biopsies for histology and culture studies established the diagnosis of Fusarium infection. They received treatment with systemic …

MaleFusariummedicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentDermatologyNeutropeniaImmunocompromised HostYoung AdultFatal OutcomeAmphotericin BGranulocyte Colony-Stimulating FactormedicineHumansYoung adultImmunodeficiencyVoriconazoleChemotherapyAspergillusbiologybusiness.industryMortality rateMiddle AgedPrecursor Cell Lymphoblastic Leukemia-LymphomaTriazolesmedicine.diseasebiology.organism_classificationDermatologyPyrimidinesFusariosisImmunologyFemaleVoriconazolebusinessmedicine.drugEuropean Journal of Dermatology
researchProduct

Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B

2009

Objectives To analyse the potential antagonism between azoles, which inhibit ergosterol synthesis, and polyenes, which bind directly to ergosterol in cell membranes, in patients receiving sequential azole-polyene treatment. Methods In an earlier randomized, double blind study of liposomal amphotericin as initial therapy for invasive filamentous fungal infection (IFFI), a 3 mg/kg/day dose had a favourable overall response rate of 50% and 12 week survival rate of 72%. No improved outcome was seen with 10 mg/kg/day for the first 14 days. The study population was further analysed for the effect of prior azole exposure on treatment responses to liposomal amphotericin B. The protocol allowed prio…

AdultAzolesMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentmedicine.drug_classAntibioticsPharmacologyAspergillosisGastroenterologyYoung AdultPharmacotherapyDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BmedicineHumansDrug InteractionsPharmacology (medical)ChildSurvival rateMycosisAgedPharmacologyVoriconazolechemistry.chemical_classificationbusiness.industryInfantMiddle Agedmedicine.diseaseTreatment OutcomeInfectious DiseasesMycoseschemistryChild PreschoolAzoleFemalebusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct